Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Coding the noncoding: 2 years of advances in the field of microRNAs and long noncoding RNAs

Cancer Gene Therapy volume 28, pages 355–358 (2021)Cite this article

Subjects

To the Editor:

Noncoding RNAs are housekeeping and regulatory RNAs that are not translated into proteins. Among them, microRNAs (miRNAs), 22 nt long small RNAs, and long noncoding RNAs (lncRNAs), defined as noncoding RNAs longer than 200 nt, are the most investigated because known to be involved in many diseases [1].

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Ratti M, Lampis A, Ghidini M, Salati M, Mirchev MB, Valeri N. MicroRNAs (miRNAs) and long non-coding RNAs (lncRNAs) as new tools for cancer therapy: first steps from bench to bedside. Target Oncol. 2020;15:261–78.

    Article  Google Scholar 

  2. Gentilin E, Tagliati F, Filieri C, Molè D, Minoia M, Ambrosio MR, et al. miR-26a plays an important role in cell cycle regulation in ACTH-secreting pituitary adenomas by modulating protein kinase Cδ. Endocrinology. 2013;154:1690–700.

    Article  CAS  Google Scholar 

  3. Zalewski DP, Ruszel KP, Stępniewski A, Gałkowski D, Bogucki J, Komsta L, et al. Dysregulation of microRNA modulatory network in abdominal aortic aneurysm. J Clin Med. 2020;9:1974.

    Article  CAS  Google Scholar 

  4. Gandellini P, Folini M, Longoni N, Pennati M, Binda M, Colecchia M, et al. miR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon. Cancer Res. 2009;69:2287–95.

    Article  CAS  Google Scholar 

  5. Gentilin E, degli Uberti E, Zatelli MC. Strategies to use microRNAs as therapeutic targets. Best Pract Res Clin Endocrinol Metab. 2016;30:629–39.

    Article  CAS  Google Scholar 

  6. Feng YH, Tsao CJ. Emerging role of microRNA-21 in cancer. Biomed Rep. 2016;5:395–402.

    Article  CAS  Google Scholar 

  7. Panagal M, Kumar S, Sivakurunathan P, Biruntha M, Karthigeyan M, Gopinathe V, et al. MicroRNA21 and the various types of myeloid leukemia. Cancer Gene Ther. 2018;25:161–6.

    Article  CAS  Google Scholar 

  8. Sekar D, Mani P, Biruntha M, Sivagurunathan P, Karthigeyan M. Dissecting the functional role of microRNA 21 in osteosarcoma. Cancer Gene Ther. 2019;26:179–82.

    Article  CAS  Google Scholar 

  9. Hua Y, Jin Z, Zhou F, Zhang YQ, Zhuang Y. The expression significance of serum MiR-21 in patients with osteosarcoma and its relationship with chemosensitivity. Eur Rev Med Pharmacol Sci. 2017;21:2989–94.

    CAS  PubMed  Google Scholar 

  10. Zhang W, Cheng P, Hu W, Yin W, Guo F, Chen A, et al. Inhibition of microRNA-384-5p alleviates osteoarthritis through its effects on inhibiting apoptosis of cartilage cells via the NF-κB signaling pathway by targeting SOX9. Cancer Gene Ther. 2018;25:326–38.

    Article  CAS  Google Scholar 

  11. Sun X, Cui M, Tong L, Zhang A, Wang K. Upregulation of microRNA-3129 suppresses epithelial ovarian cancer through CD44. Cancer Gene Ther. 2018;25:317–25.

    Article  CAS  Google Scholar 

  12. Wu D, Zhang J, Lu Y, Bo S, Li L, Wang L, et al. miR-140-5p inhibits the proliferation and enhances the efficacy of doxorubicin to breast cancer stem cells by targeting Wnt1. Cancer Gene Ther. 2019;26:74–82.

    Article  CAS  Google Scholar 

  13. Chandimali N, Huynh DL, Zhang JJ, Lee JC, Yu D, Jeong DK, et al. MicroRNA-122 negatively associates with peroxiredoxin-II expression in human gefitinib-resistant lung cancer stem cells. Cancer Gene Ther. 2019;26:292–304.

    Article  CAS  Google Scholar 

  14. Yue D, Qin X. miR-182 regulates trastuzumab resistance by targeting MET in breast cancer cells. Cancer Gene Ther. 2019;26:1–10.

    Article  CAS  Google Scholar 

  15. Zhou X, Men X, Zhao R, Han J, Fan Z, Wang Y, et al. miR-200c inhibits TGF-β-induced-EMT to restore trastuzumab sensitivity by targeting ZEB1 and ZEB2 in gastric cancer. Cancer Gene Ther. 2018;25:68–76.

    Article  CAS  Google Scholar 

  16. Zhao T, Chen Y, Sheng S, Wu Y, Zhang T. Upregulating microRNA-498 inhibits gastric cancer proliferation invasion and chemoresistance through inverse interaction of Bmi1. Cancer Gene Ther. 2019;26:366–73.

    Article  CAS  Google Scholar 

  17. Zhou H, Sun Z, Li S, Wang X, Zhou X. LncRNA SPRY4-IT was concerned with the poor prognosis and contributed to the progression of thyroid cancer. Cancer Gene Ther. 2018;25:39–46.

    Article  Google Scholar 

  18. Li S, Zhang S, Chen J. c-Myc induced upregulation of long non-coding RNA SNHG16 enhances progression and carcinogenesis in oral squamous cell carcinoma. Cancer Gene Ther. 2019;26:400–10.

    Article  Google Scholar 

  19. Cao X, Xu J, Yue D. LncRNA-SNHG16 predicts poor prognosis and promotes tumor proliferation through epigenetically silencing p21 in bladder cancer. Cancer Gene Ther. 2018;25:10–17.

    Article  CAS  Google Scholar 

  20. Li SY, Wang H, Mai HF, Li GF, Chen SJ, Li GS, et al. Down-regulated long non-coding RNA RNAZFHX4-AS1 suppresses invasion and migration of breast cancer cells via FAT4-dependent Hippo signaling pathway. Cancer Gene Ther. 2019;26:374–87.

    Article  CAS  Google Scholar 

  21. Li X, Li Z, Liu Z, Xiao J, Yu S, Song Y. Long non-coding RNA DLEU1 predicts poor prognosis of gastric cancer and contributes to cell proliferation by epigenetically suppressing KLF2. Cancer Gene Ther. 2018;25:58–67.

    Article  CAS  Google Scholar 

  22. Zhong Y, Yu C, Qin W. LncRNA SNHG14 promotes inflammatory response induced by cerebral ischemia/reperfusion injury through regulating miR-136-5p /ROCK1. Cancer Gene Ther. 2019;26:234–47.

    Article  CAS  Google Scholar 

  23. Kopp F, Mendell JT. Functional Classification and Experimental Dissection of Long Noncoding RNAs. Cell. 2018;172:393–407.

    Article  CAS  Google Scholar 

  24. Profumo V, Forte B, Percio S, Rotundo F, Doldi V, Ferrari E, et al. LEADeR role of miR-205 host gene as long noncoding RNA in prostate basal cell differentiation. Nat Commun. 2019;10:307.

    Article  Google Scholar 

  25. Liu LLY, Zhang R, Li C, Xiong J, Wei Y. MIR205HG acts as a ceRNA to expedite cell proliferation and progression in lung squamous cell carcinoma via targeting miR-299-3p/MAP3K2 axis. BMC Pulm Med. 2020;20:163.

    Article  CAS  Google Scholar 

  26. Di Agostino SVF, Sacconi A, Fontemaggi G, Pallocca M, Pulito C, Ganci F, et al. Long non-coding MIR205HG depletes Hsa-miR-590-3p leading to unrestrained proliferation in head and neck squamous cell carcinoma. Theranostics. 2018;8:1850–68.

    Article  CAS  Google Scholar 

  27. Wang J, Chen J, Sen S. MicroRNA as biomarkers and diagnostics. J Cell Physiol. 2016;231:25–30.

    Article  CAS  Google Scholar 

  28. El Bezawy R, De Cesare M, Pennati M, Deraco M, Gandellini P, Zuco, et al. Antitumor activity of miR-34a in peritoneal mesothelioma relies on c-MET and AXL inhibition: persistent activation of ERK and AKT signaling as a possible cytoprotective mechanism. J Hematol Oncol. 2017;10:19.

    Article  Google Scholar 

  29. Gandellini P, Doldi V, Zaffaroni N. microRNAs as players and signals in the metastatic cascade: Implications for the development of novel anti-metastatic therapies. Semin Cancer Biol. 2017;44:132–40.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank Dr. Milvia Chicca for revising the preliminary paper and providing suggestions.

Funding

The work is supported by grants from Italian Ministry of Health (GR-2013-02355625 to PG) and CARIPLO Foundation (2015-0866 to PG).

Author information

Author notes

  1. These authors contributed equally: Erica Gentilin, Paolo Gandellini

Authors and Affiliations

  1. Bioacoustics Research Laboratory, Department of Neurosciences, University of Padua, via G. Orus, 2b, 35129, Padua, Italy

    Erica Gentilin

  2. Department of Biosciences, University of Milan, Via Celoria 26, 20133, Milan, Italy

    Paolo Gandellini

Authors
  1. Erica Gentilin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paolo Gandellini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Erica Gentilin or Paolo Gandellini.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gentilin, E., Gandellini, P. Coding the noncoding: 2 years of advances in the field of microRNAs and long noncoding RNAs. Cancer Gene Ther 28, 355–358 (2021). https://doi.org/10.1038/s41417-020-00236-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41417-020-00236-x

This article is cited by

Search

Advanced search

Quick links